



Cultural Organization + Roma, Italy







July 3-4 2020

15:00-18:30 **Rome Time**

Bioethics during COVID-19

















Ethical Challenges in Biomedical Research of COVID-19 Vaccine and Therapy

Zoom Webinar

Prof. Alberto García Gómez

agarcia@unescobiochair.org

OUTLINE

- 1. COVID-19 Challenges Research: Prevention and Treatment
- 2. Researchers' Shared Concerns
- 3. Shortenting the Terms: Fast Pace in Vaccine Development? Possible? Ethical?
- 4. Ethical Standards for Research During Public Health Emergencies
- 5. Some principles in respect of human dignity and human rights: Autonomy, Safety, Security, Efficacy & Justice Store

COVID-19 Ethical Challenges Research prevention & treatment


- 1. Vaccine development: to shorten the terms
- 2. Massive vaccine <u>production</u>: produced on a scale never before known
- 3. Vaccination campaings: secure and massive
- 4. Treatment using new and/or current drugs in combination: Internationally, there are an estimated 200 new drugs under investigation

Researchers' Shared Concerns & Ethical Challenges:

- Arrive on time (accelerate processes): efficacy vs success and notoriety
- Union of forces: comunitarian cooperation vs individual (company) profit

Shortenting the Terms Biomedical Research Phases


Clinical Trials



Shortenting the Terms

New emerging diseases vaccine development timeline

Source: natureresearch



Shortenting the Terms Classical vs COVID-19 vaccines

Classical vaccines

1

Preclinical stage

(18-30 months)

Û

Phase I (dozens of volunteers~30 months)

0

Phase II (hundreds of volunteers ~32 months)

O.

Phase III (thousands of volunteers ~30 months)

O.

Approval, Manufacture, Vaccination (12-24 months) **COVID-19 vaccines**

1

Preclinical stage (0 months)

O.

Phase I (dozens of volunteers ~ 6 months)

O

Phase II (hundreds of volunteers ~ 6 months)


O

Phase III (thousands of volunteers ~ 0 months)

O.

Approval, Manufacture, Vaccination (billions of doses/individuals~ 6 months)

What is going on? COVID-19 vaccine R&D landscape



A new era in vaccinology? COVID-19 vaccine R&D landscape

Recombinant genetic technology has contributed to setting an unprecedented fast pace in vaccine development, clearly demonstrated during the recent COVID-19 pandemic:

-Control of epidemics has been achieved successfully thanks to vaccines developed using various technologies, predominantly by classic pathogen inactivation or attenuation. This has worked efficiently for Cholera, Typhoid, Polio, Measles, Plague or Tetanus -The pace of these vaccine developments is comparatively slow to that imprinted by 21st-century vaccines that use recombinant genetic technology. During the recent pandemic of COVID-19, six vaccine candidates encoding or presenting SARS-CoV-2 antigens have entered phase I clinical trials

Ethical standards for research during public health emergencies:

Scientific validity	Social value
Collaborative partnership	Reasonable risk-benefit ratio
Fair and voluntary participation	Independent review

- They <u>should be adhered</u> to by researchers, review bodies, funders, publishers, and manufacturers during an emergency
- These universal ethical standards <u>may be adapted</u> to particular circumstances and contexts.

Ethical standards for research during public health emergencies:

- 1. Research should be conducted only if it does **not impede emergency response** efforts.
- Research projects should be coordinated nationally and internationally to avoid wasteful duplication and underpowered studies
- 3. Fair and meaningful community **engagement** and inclusive decision-making.
- 4. Research involving human participants requires independent **ethics review**.
- 5. Informed consent: reasonable scientific basis to believe that the study intervention is likely to be safe and efficacious and that risks to participants have been minimized to the extent reasonably possible.

Vulnerability in biomedical research

- Engagement of people as participants in clinical research is key in providing solutions to, and understanding of, medical problems afflicting humankind
- The interests of researchers and subjects are not always aligned as they are in the relationship between healthcare professionals and patients
- Strong desire to pursue useful generalisable knowledge gives rise to the temptation to underprotect or ignore the participants' well being

What we should do in respect of the vulnerable?

- To identify individuals and groups exposed to be negatively affected: harmed, threatened or at risk in their well-being and basic needs.
- To assume commitment to identify threats to well-being and appropriate means to foster human dignity, human rights and fundamental freedoms
- To mitigate threats to the vulnerable persons, or eliminating the conditions that underlie vulnerability.
- To protect from all forms of exploitation or abuse, but at the same time must not be excluded from potential benefits of research









Ethical Challenges in Biomedical Research of COVID-19 Vaccine and Therapy

Zoom Webinar

Prof. Alberto García Gómez

agarcia@unescobiochair.org